Working… Menu

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Insulin (IN-105) in Type 1 Diabetes Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01035801
Recruitment Status : Terminated (This study was temporarily paused due to an unanticipated bioanalytical issue.)
First Posted : December 21, 2009
Last Update Posted : January 23, 2018
Information provided by (Responsible Party):
Biocon Limited

Brief Summary:
The purpose of this study is to see whether IN-105 (oral insulin) is able to control increase in blood glucose after eating a meal. This study will also tell whether single tablet of IN-105 is safe for patients with Type 1 diabetes mellitus who are currently taking insulin injections.

Condition or disease Intervention/treatment Phase
Type 1 Diabetes Mellitus Drug: IN-105 Drug: Insulin Lispro Injection Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 20 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An OpenLabel, Multicenter, Non-randomized, ActiveControlled, SingleDose Escalation, Study to Evaluate the Pharmacodynamics,Pharmacokinetics,Safety, and Tolerability of IN-105 Under Fed Conditions In Patients With Type 1 Diabetes Mellitus
Actual Study Start Date : August 21, 2010
Actual Primary Completion Date : March 12, 2011
Actual Study Completion Date : March 12, 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Diabetes Type 1

Arm Intervention/treatment
Experimental: IN105
Prandial Oral Insulin
Drug: IN-105
Prandial Oral Insulin

Active Comparator: Insulin Lispro Injection Drug: Insulin Lispro Injection
Insulin Lispro Injection

Primary Outcome Measures :
  1. AUC (Insulin and Blood Glucose) [ Time Frame: 0-130 min ]

Secondary Outcome Measures :
  1. AUC (Insulin and Blood Glucose) [ Time Frame: 0-70 min, 0-190 min and 0-250 min ]
  2. Frequency of Adverse Events [ Time Frame: 9 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Male and female patients between the ages of 18-45 years inclusive
  2. Established diagnosis of T1DM for at least 1-year
  3. Body mass index of 18.5-29.9 kg/m2 inclusive
  4. Stable weight with no more than 5 kg gain or loss within 3 months of screening
  5. HbA1c ≤ 8.0%
  6. On stable insulin or an insulin analogue regimen for at least 3 months

Exclusion Criteria:

  1. Any hypersensitivity or allergy
  2. Positive urine ketones test at screening visit.
  3. ECG abnormality
  4. total daily insulin >1 IU/kg and/or >0.7 IU/Kg of basal insulin and/or >0.6 IU/Kg of prandial insulin.
  5. Patient with a clinically significant abnormality
  6. Evidence of severe secondary complications of diabetes
  7. History of drug or alcohol dependence or abuse
  8. Patients currently on systemic or inhaled glucocorticoids or other drugs, which may affect glycemic control.
  9. Patients treated with blood-glucose lowering drugs other than insulin or insulin analogues in the last 4 weeks prior to screening or during the study
  10. History of two or more severe episodes of hypoglycemia (defined by ADA criteria) within 6 months prior to screening and/or patients with history of low blood glucose level episodes suggestive of hypoglycemia unawareness (loss of warning symptoms of hypoglycemia). Investigator to assess this criterion based on the subject filled questionnaire.
  11. Any hospitalization or emergency room visit due to poor diabetes control within 6 months prior to screening.
  12. Impaired hepatic function (ALT or AST value greater than 2 X Upper limit of reference range and/or serum bilirubin ≥1.5 X Upper limit of reference range at the screening visit).
  13. Impaired renal function (serum creatinine ≥1.5 X Upper limit of reference range at screening).
  14. Hemoglobinopathies, haemolytic anaemia, anaemia of chronic disease, or any factor affecting the measurement of HbA1c.
  15. Any electively planned surgery requiring hospitalization during the study period.
  16. Pregnancy, lactation, or planned pregnancy during the study duration.
  17. The patient has received another investigational drug within 6 weeks prior to screening
  18. Mental incapacity, unwillingness or language barriers precluding adequate understanding or co-operation.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01035801

Layout table for location information
Care Hospital
Hyderabad, Andhra Pradesh, India, 500034
Bharti Research Institute of Diabetes and Endocrinology
Karnal, Hariyana, India, 132001
Diacon Hospital,(Diabetes Care and Research Centre)
Bangalore, Karnataka, India, 560010
Bangalore Diabetes Hospital
Bangalore, Karnataka, India, 560052
Belgaum Diabetic Centre
Belgaum, Karnataka, India, 590001
Sponsors and Collaborators
Biocon Limited
Layout table for investigator information
Principal Investigator: Dr. K.M. Prasanna Kumar, MD, DM CEO and Consultant Endocrinologist, Bangalore Diabetes Hospital, #16/M, Miller tank Bed Area, Thimmaiah Road, Vasanthnagar, Bangalore-560052
Principal Investigator: Dr. Aravind R Sosale, DNB Director, Diacon Hospital,Diabetes Care and Research Centre, 359-360, 19th Main, Ist Block,Rajajinagar,Bangalore-560010.
Principal Investigator: Dr. Sanjay Kalra, MD, DM Bharti Research Institute of Diabetes & Endocrinology (BRIDE), Bharti Hospital, Wazir Chand Colony, Kunjpura, karnal, Hariyana- 132001
Principal Investigator: Dr Bipin Kumar Sethi, MD, DM Care Hospital, Road 1, Banjara Hills, Hyderabad - 500034
Principal Investigator: Dr. Neeta Deshpande, MD Belgaum Diabetic Centre, Ground floor,Beside mahila Vastu Bhander, Maruti Gali, Belgaum- 590001
Layout table for additonal information
Responsible Party: Biocon Limited Identifier: NCT01035801    
Other Study ID Numbers: IN105-CT1-005-09
First Posted: December 21, 2009    Key Record Dates
Last Update Posted: January 23, 2018
Last Verified: January 2018
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Diabetes Mellitus, Type 1
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases
Insulin Lispro
Hypoglycemic Agents
Physiological Effects of Drugs